Search

Yan S Poon

from South San Francisco, CA
Age ~46
Get Report
Also known as:
Shuen Poon Yan, Poon Yan, Yan Poom
Related to:
Truc Thien Tang, 51Jan S PoonChung S Poon, 52Chie C Poon, 81Shirley O Poon, 78
Connected to:
Alan W Poon, 55Albert B Poon, 88Angel Poon, 37Angie F Poon, 58Candice Poon, 30Clemar M Poon, 56Colin Poon, 61Daisy S Poon, 41Dolly L Poon, 88Elena A Poon, 44

Yan Poon Phones & Addresses

  • South San Francisco, CA
  • Daly City, CA
  • Millbrae, CA
  • Brisbane, CA
  • Berkeley, CA
  • San Diego, CA
  • Pasadena, CA
  • San Jose, CA
  • San Gabriel, CA
  • Los Angeles, CA

Resumes

Resumes

Yan Poon Photo 1

Vp, Biology

View page
Location:
887 south Mayfair Ave, Daly City, CA 94015
Industry:
Biotechnology
Work:
Unity Biotechnology
Vp, Biology
Sapphire Energy Sep 2014 - Jun 2015
Vice President of Research and Development
Sapphire Energy Apr 2011 - Sep 2014
Director, Biotechnology
Sapphire Energy Dec 2009 - Apr 2011
Section Leader
Sapphire Energy Jun 2009 - Dec 2009
Scientist Ii
Education:
Caltech 2002 - 2008
Doctorates, Doctor of Philosophy, Chemistry University of California, Berkeley 1996 - 2000
Bachelors, Bachelor of Arts, Bachelor of Science, Biology, Music, Chemistry Leland High School
Skills:
Biochemistry
Molecular Biology
Biotechnology
Protein Chemistry
Protein Purification
Drug Discovery
Protein Expression
Microbiology
Chemistry
Cell Culture
Lifesciences
Pcr
Genomics
Dna
Mass Spectrometry
Technology Transfer
Cell Biology
Bioinformatics
Yan Poon Photo 2

Yan Poon

View page

Publications

Us Patents

Methods Of Inhibiting Pathological Angiogenesis

View page
US Patent:
20200253991, Aug 13, 2020
Filed:
Feb 14, 2020
Appl. No.:
16/791960
Inventors:
- Brisbane CA, US
Jill Hopkins - Brisbane CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
International Classification:
A61K 31/635
A61P 27/02
Abstract:
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

Technology To Inhibit Progression Of Neovascularization And Vaso-Obliteration

View page
US Patent:
20190151337, May 23, 2019
Filed:
Oct 15, 2018
Appl. No.:
16/160840
Inventors:
- Brisbane CA, US
- Novato CA, US
Harry Sweigard - Brisbane CA, US
Yan Poon - Brisbane CA, US
Jamie Dananberg - Brisbane CA, US
Daniel Marquess - Brisbane CA, US
Nathaniel David - Brisbane CA, US
International Classification:
A61K 31/635
A61K 9/00
A61P 27/02
Abstract:
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.
Control profile
Yan S Poon from South San Francisco, CA, age ~46 Get Report